01:45 AM EDT, 09/22/2026 (MT Newswires) -- Roche (RO.SW) said Tuesday that once-weekly enicepatide met the primary endpoints of a phase 2 study after it helped reduce blood glucose and body weight in adults with type 2 diabetes and overweight or obesity. Results from the mid-stage trial called CT-388-104 showed that patients administered with 24-milligram enicepatide, the highest titrated dose, showed a 2.65% reduction in blood sugar levels and a mean weight loss of 15.5% after 48 weeks. In addition, 90% of patients in the 24-mg group achieved a blood sugar level of less than or equal to 6.5%, while 62% reached normal blood glucose levels. Enicepatide's safety and tolerability profile was in line with other established incretin-based therapies. The Swiss drugmaker is conducting a late-stage development program for enicepatide, including two ongoing late-stage trials in chronic weight management, with plans for a phase 3 glycemic-control program and cardiovascular outcomes studies in the first half of 2027.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.